Remote Cognitive Screening Platform Expands Access to Early Detection

©Visualmind/AdobeStock

Anywhere powered by Linus Health™ has expanded its reach beyond traditional clinical settings to include payers, pharmaceutical companies, wellness providers, and consumers, according to a July 28, 2025, announcement from Linus Health.¹

The Anywhere platform is a clinically validated, AI-driven cognitive assessment platform designed to detect early signs of cognitive impairment. The platform enables individuals to complete brief, browser-based cognitive assessments and questionnaires remotely, on their own devices. The technology leverages AI and digital neuroscience to detect subtle cognitive changes often missed by conventional tools.¹

“Early detection of cognitive impairment is critical—and it shouldn’t be limited to a clinic setting,” David Bates, PhD, CEO and co-founder of Linus Health, said in a press release. “With Anywhere, we’re making clinical-grade brain health tools accessible at scale—whether you’re a payer building a preventive care model, a wellness company promoting cognitive fitness, or an individual taking charge of your own brain health.”¹

Global dementia prevalence is increasing rapidly: approximately 55–57 million people worldwide were living with dementia in 2021, with nearly 10 million new cases annually. Projections estimate cases could nearly triple to over 150 million by 2050.^2,3 In the US, an estimated 7.2 million Americans aged 65 and older have Alzheimer disease in 2025, with that number projected to reach nearly 13.8 million by 2060 barring medical breakthroughs.^4,5 These trends underscore urgent need for early screening and scalable tools capable of supporting proactive brain health across populations.

The expanded platform is built on an API-first infrastructure, allowing seamless integration with third-party systems, such as payer portals, employer wellness applications, remote clinical trial platforms, and digital therapeutics. According to John Showalter, MD, MSIS, chief operating officer at Linus Health, “Our API makes it simple for organizations to bring clinical-grade cognitive insights into their own digital ecosystems and workflows.”¹

Key benefits by user type include¹:

• Payers: Support for value-based care initiatives and population-wide brain health strategies.
• Pharmaceutical companies: Facilitation of decentralized trial screening, participant stratification, and real-world data generation.
• Wellness providers: Differentiated services to monitor and support cognitive performance.
• Consumers: Tools for proactive cognitive health tracking and self-monitoring.

The expanded availability follows successful community screening pilots that demonstrated both platform usability and demand for accessible, proactive brain health solutions. Pilot participants reported ease of use, and the platform demonstrated reliability across diverse demographic groups, according to the press release.¹

References:

1. Anywhere powered by Linus Health™ Expands Equitable Access to Early Detection of Cognitive Impairment. News release. Linus Health. July 28, 2025. Accessed July 29, 2025. https://linushealth.com/press-releases/anywhere-powered-by-linus-health-expands-equitable-access-to-early-detection-of-cognitive-impairment
2. World Health Organization. Dementia fact sheet. Updated September 20, 2023. Accessed July 29, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia
3. Alzheimer’s Research UK. Worldwide dementia cases to triple by 2050 to over 150 million. Published January 6, 2022. Accessed July 29, 2025. https://www.alzheimersresearchuk.org/news/worldwide-dementia-cases-to-triple-by-2050-to-over-150-million
4. Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer disease and related dementias in the United States (2025–2060) in adults aged ≥65 years. Alzheimers Dement. 2024;20(5):3708-3821. doi:10.1002/alz.13809
5. Koma W, Cubanski J, Neuman T. Alzheimer’s disease and other dementias: a growing burden on Medicare and Medicaid. JAMA. Published online May 15, 2025. doi:10.1002/alz.70235